Clinical trial results show the drugs reduce risk of death by 24% for critically ill patients and time spent in intensive care by up to ten days.
Patients across the UK who are admitted to intensive care units due to COVID-19 are set to receive new life-saving treatments which can reduce the time spent in hospital by up to ten days, the government has announced today (Thursday 7 January).
Results from the government-funded REMAP-CAP clinical trial published today showed tocilizumab and sarilumab reduced the relative risk of death by 24%, when administered to patients within 24 hours of entering intensive care.
Most of the data came from when the drugs were administered in addition to a corticosteroid, such as dexamethasone – also discovered through government-backed research through the RECOVERY clinical trial – which is already provided as standard of care to the NHS.
Patients receiving these drugs, typically used to treat rheumatoid arthritis, left intensive care between 7 to 10 days earlier on average. The rollout of these treatments could therefore contribute significantly towards reducing pressures on hospitals over the coming weeks and months.
Updated guidance will be issued tomorrow by the government and the NHS to trusts across the UK, encouraging them to use tocilizumab in their treatment of COVID-19 patients who are admitted to intensive care units, effective immediately.
Supplies of tocilizumab are already available in hospitals across the UK and clinicians will be able to treat all those admitted to intensive care units, potentially saving hundreds of lives. The department is working closely with Roche, who manufacture tocilizumab, to ensure treatments continue to be available to UK patients.
Health and Social Care Secretary Matt Hancock said:
Deputy Chief Medical Officer Professor Jonathan Van-Tam said:
In June last year, the UK government approved dexamethasone as the world’s first treatment proven to reduce mortality for COVID-19. The REMAP-CAP trial found that the rate of death for those in intensive care units on corticosteroids, such as dexamethasone, and respiratory support alone was 35%, which was reduced to 28% when tocilizumab was also administered.
The government continues to work in partnership to ensure global equitable access to safe and effective treatments. Only multilateral collaboration can deliver at the speed and scale needed to end the global pandemic, and the government remains committed to participating in international trials such as this that seek to answer important questions about the virus.
The UK has played an integral role in these international efforts: three-quarters of patients enrolled globally have been NHS patients, in 142 hospitals across the UK – roughly half of the 289 total sites across the world. A quarter of all patients in intensive care with COVID-19 have enrolled and continue to volunteer to enrol in the REMAP-CAP trial – all of whom have made a vital contribution to the research needed to beat this disease.
Support also came from the UK’s National Institute for Health Research (NIHR), its well-established Clinical Research Network and the UK’s Chief Medical Officers. The UK government has, to date, provided £1.2 million to support the REMAP-CAP trial.
Professor Stephen Powis, NHS national medical director, said: